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Most patients with oesophageal cancer have locally advanced
unresectable or metastatic disease before symptoms occur. They
may present with difficulty in swallowing, indigestion, weight loss,
anorexia or occasionally pain on swallowing. The mainstay of
diagnosis is by endoscopy and biopsy. Computed tomography
scans of the chest, abdomen and pelvis are usually performed to
complete staging. In the last decade, endoscopic ultrasonography
(EUS) has assumed a central role in the initial anatomic staging of
oesophageal cancer because of its accuracy in assessing the extent
of locoregional disease (Vilgrain et al, 1990; Botet et al, 1991;
Rosch et al, 1992). However, EUS was unlikely to have been widely
used before 2001 and thus any impact on survival from better
case selection will not be apparent in the data published by Mitry
et al (2008).
During the period of this analysis, surgery was considered the
treatment of choice for localised adenocarcinoma in England and
Wales and for those patients who underwent curative resection the
median survival was 25 months. In 2002, however, a large
randomised Medical Research Council (MRC Oesophageal Cancer
Working Group, 2002) study reported a survival benefit for
neoadjuvant chemotherapy plus surgery compared with surgery
alone. This trial randomly allocated 802 previously untreated
patients to two cycles of 5FU/cisplatin preoperatively followed by
surgical resection vs surgery alone. The 2-year survival was 43%
compared with 34% respectively (P¼0.004). These data changed
clinical practice in this country and preoperative chemotherapy
with 5FU/cisplatin has become the standard of care for potentially
operable oesophageal adenocarcinoma. Chemoradiation is the
therapy of choice for patients who are deemed unfit for surgery but
whose staging shows localised squamous cell carcinoma or
adenocarcinoma.
For advanced oesophageal tumours, there was a shift in the
treatment paradigm in the 1990s when several studies demon-
strated a survival advantage for chemotherapy over best suppor-
tive care. A number of combination chemotherapy regimens were
then evaluated in this setting, and epirubicin, cisplatin and infused
5FU (ECF) demonstrated superior efficacy, (median overall
survival (OS) of 9.4 months) and quality of life in several
randomised trials (Webb et al, 1997; Waters et al, 1999; Ross
et al, 2002). Epirubicin, cisplatin and infused 5FU became the
regimen of choice for advanced oesophageal cancer in the UK from
1999 onwards.
A national study of 1002 patients evaluated the substitution of
capecitabine for infused 5FU and oxaliplatin for cisplatin vs
the original ECF regimen in patients with previously
untreated advanced oesophago-gastric cancer. Capecitabine and
oxaliplatin were as effective as 5FU and cisplatin. Furthermore, OS
was longer with epirubicin, oxaliplatin and capecitabine (EOX)
than ECF (median OS of 11.4 months) with a hazard ratio for
death for EOX of 0.80, 95% CI: 0.66–0.97; (P¼0.02) (Cunningham
et al, 2008).
Relative 1-year survival increased significantly between the
late 1980s and 1990s.This is likely to be partly because of a
decrease in postoperative mortality rates. Jamieson et al
reviewed postoperative mortality rates between 1990 and 2000
and reported an overall mortality rate of 6.7%, which is lower than
earlier decades. This rate has continued to fall and the acceptable
value is now less than 5% although the postoperative mortality rate
for the surgery alone arm in the MRC study was 9% (Jamieson
et al, 2004). It is now recognised that the outcome after
oesophagectomy is strongly related to the institutional volume
(number of cases resected per annum) and thus surgical centres
have been established nationally (Birkmeyer et al, 2002; Dimick
et al, 2003).
The change in survival may also be attributable to the
implementation of chemotherapy for advanced disease towards
the late 1990s. There is an increase in 5-year survival during this
time period for men although there is no change in this rate for
women. This disparity between genders remains unexplained.
The deprivation gap is more marked for 1-year survival
compared with 5- and 10-year survival. This may suggest that
this effect is not related to disease-specific factors. There is also a
widening of the deprivation gap for 5- and 10-year survival over
time suggesting that survival has risen more in the affluent than
the deprived.
Predicted survival rates from period analysis suggest a continu-
ing small increase in survival. These projections are consistent
with current progress in the management of this disease.
Endoscopic ultrasonography has become widely adopted for
staging of localised disease and FDG PET is being studied to
identify occult metastatic disease. Preoperative chemotherapy has
demonstrated a significant survival benefit and surgery is being
performed at high-volume institutions. The median OS for
advanced disease has been prolonged by chemotherapy and with
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Since the late 1990s multidisciplinary teams have been estab-
lished to ensure the optimal staging, diagnosis and management of
oesophageal cancer. The incidence of adenocarcinoma of the
oesophagus is increasing and since Barrett’s oesophagus has been
identified as the main risk factor, research efforts are focusing on
intervention and surveillance programmes for this indication.
Other molecular and genetic studies are also underway to try and
identify prognostic factors that may correlate with clinical outcome.
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